BridgeBio have substantially advanced its development of an new therapy for ATTR-CM, leveraging Attruby. Early patient results indicates promising benefits for individuals suffering by the severe illness. This effort https://biotech304476.dbblog.net/15473287/bridgebio-progresses-attr-cm-management-with-the-drug